Assessing the safety of beta‐blocker therapy in cirrhosis patients with ascites: A meta‐analysis.

Background & Aims: Beta‐blocker therapy is effective at reducing risks of variceal bleeding. However, beta‐blockers may detrimentally exacerbate the underlying haemodynamic changes in cirrhosis. A systematic review and meta‐analysis was performed to evaluate impact of beta‐blockers on all‐cause mortality among cirrhosis patients with ascites. Methods: A literature search identified studies that evaluated beta‐blocker vs no beta‐blocker therapy in cirrhosis patients with ascites. The primary outcome was all‐cause mortality with subcohort analysis of patients with refractory or severe ascites. Quality of observational studies was assessed with Newcastle‐Ottawa Scale and overall certainty of the evidence was assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Results: Eight observational studies, representing 3627 cirrhosis patients with ascites (1630 treated with beta‐blockers and 1997 not treated), were included. Pooled all‐cause mortality was 38.6% in beta‐blocker group vs 42.2% in no beta‐blocker group (RR 0.93, 95% CI 0.77‐1.13, χ2 = 54.03, I2 = 87%). Subcohort analysis of cirrhosis patients with refractory or severe ascites demonstrated 33.3% mortality in beta‐blocker group vs 32.1% in no beta‐blocker group (RR 0.99, 95% CI 0.70‐1.40, χ2 = 32.99, and I2 = 82%). Three studies were good quality and five studies were fair quality. GRADE rating was 'very low' certainty of evidence, given concern for bias and inconsistency stemming from significant heterogeneity. Conclusion: No significant increase in all‐cause mortality was observed in cirrhosis patients with ascites treated with beta‐blockers. However, given the low certainty of the evidence, high quality prospective studies are needed. [ABSTRACT FROM AUTHOR]